# Avo In R/R And Previously Untreated MCL

> **NCT04855695** · PHASE1,PHASE2 · RECRUITING · sponsor: **Austin I Kim** · enrollment: 72 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Refractory Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04855695
- **Lead sponsor:** Austin I Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-02
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- Roche-Genentech
- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855695, "Avo In R/R And Previously Untreated MCL". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04855695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*